Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer
Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1910962?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed
This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)
Questions To Ask Your Health Care Provider
- I have finished my first-line treatment. Should I consider maintenance therapy?
- What are my options for maintenance therapy after chemotherapy?
- What type of side effects should I expect on a PARP inhibitor?
Open Clinical Trials
The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.